These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22845476)

  • 1. Companion diagnostics: emerging strategies and issues in pharmaceutical development.
    Thomas J; Stratton E; Keppens M
    Expert Rev Mol Diagn; 2012 Jul; 12(6):561-3. PubMed ID: 22845476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop.
    Hinman L; Spear B; Tsuchihashi Z; Kelly J; Bross P; Goodsaid F; Kalush F
    Pharmacogenomics; 2009 Jan; 10(1):127-36. PubMed ID: 19102722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs and diagnostic innovations to improve global health.
    Peeling RW; Nwaka S
    Infect Dis Clin North Am; 2011 Sep; 25(3):693-705, xi. PubMed ID: 21896368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International differences in companion diagnostic approvals: how are we able to manage the differences?
    Shimazawa R; Ikeda M
    Expert Rev Mol Diagn; 2015 Feb; 15(2):157-9. PubMed ID: 25308218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and regulatory strategies for drug and diagnostic co-development.
    Hinman LM; Carl KM; Spear BB; Salerno RA; Becker RL; Abbott BM; Kelly JF; Mansfield E; Katz RG; Harper C; Day SP; Pacanowski MA; Pignato W
    Pharmacogenomics; 2010 Dec; 11(12):1669-75. PubMed ID: 21142909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Companion diagnostics: the next step in personalized clinical care.
    Thongkham D; Terry SF
    Genet Test Mol Biomarkers; 2012 Oct; 16(10):1155-6. PubMed ID: 23057592
    [No Abstract]   [Full Text] [Related]  

  • 7. The Regulation of Companion Diagnostics: A Global Perspective.
    Ansari M
    Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
    Roscoe DM; Hu YF; Philip R
    Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current and future state of companion diagnostics.
    Agarwal A; Ressler D; Snyder G
    Pharmgenomics Pers Med; 2015; 8():99-110. PubMed ID: 25897259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Market opportunities and technology trends in point of care diagnostics - SMi conference.
    Shirvill J
    IDrugs; 2006 Apr; 9(4):263-5. PubMed ID: 16596479
    [No Abstract]   [Full Text] [Related]  

  • 12. Do companion diagnostics make economic sense for drug developers?
    Agarwal A
    N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TB diagnostics in India: creating an ecosystem for innovation.
    Engel N; Kenneth J; Pai M
    Expert Rev Mol Diagn; 2012 Jan; 12(1):21-4. PubMed ID: 22133116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current situation and challenges in companion diagnostics development].
    Nishida M
    Gan To Kagaku Ryoho; 2014 Dec; 41(13):2529-34. PubMed ID: 25596043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preface for companion diagnostics.
    Carini C
    Ann N Y Acad Sci; 2015 Jun; 1346(1):v-vi. PubMed ID: 26099691
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges in the codevelopment of companion diagnostics.
    Moore MW; Babu D; Cotter PD
    Per Med; 2012 Jul; 9(5):485-496. PubMed ID: 29768776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis diagnostics: innovating to make an impact.
    Ghanashyam B
    Expert Rev Anti Infect Ther; 2011 Apr; 9(4):381-4. PubMed ID: 21504393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized therapeutics and companion diagnostics: a new paradigm in testing and treatment.
    Heger NE; Kellogg MD
    Clin Chem; 2014 May; 60(5):795-6. PubMed ID: 24778305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.